Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Wu YL, John T, Grohe C, Majem M, et al. J Thorac Oncol 2022;17:423-433.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu YL, John T, Grohe C, Majem M, et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol 2022;17:423-433.
PMID: 34740861